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Chapter 1 
 
Introduction & Literature Review 
 
 
 
Meningiomas are the most common benign tumors of the central nervous system, comprising 
between 12 and 15% of all intracranial neoplasms (1-4). They are of mesenchymal origin and 
arise from arachnoid cells of neurovascular structures in close proximity to cranial sutures (3). 
Sphenoid wing meningiomas are the most frequently occurring tumor of the sphenoid wing 
making up approximately 18% of all meningiomas (2, 4). Cushing and Eisenhardt were the 
first to classify sphenoid wing meningiomas into globoid, nodular and en plaque subtypes (2). 
The more common globoid entity has been sub-classified according to the anatomical location 
of the lesser sphenoid wing i.e. medial, middle and lateral. The medial third comprises the 
projection of bone from posterior to anterior most closely adjacent to the anterior clinoid 
process. The middle third lies immediately lateral to the middle third and the lateral third 
comprises the most lateral portion of bone before it joins the squamous portion of the temporal 
bone (2). This classification was further modified into medial third and lateral two thirds by 
Fohanno and Bitar, as the medial third corresponds to the posterior margin of the lesser wing 
and the lateral two thirds corresponds to the posterior margin of the greater wing (4, 5). 
En plaque meningiomas are rare and make up 2-9% of all meningiomas. They mostly occur 
in the sphenoid wing and are 3 – 6 times more common in females (6). Spheno-orbital 
meningiomas have been shown to occur almost exclusively in females (94%) (7). In the 
literature en plaque meningiomas are also referred to as pterional tumors of the sphenoid, 
hyperostosing tumors and spheno-orbital meningiomas. This subtype is characterized by a 
small volume, thin layer of tumor (meningeal component), which is out of proportion to a              
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relatively large bony hyperostosis. The hyperostosis is thought to result from direct tumor 
spread into the bone via the Haversian canal system. The bony hyperostosis identified on 
computed tomography (CT) scan must be differentiated from other conditions such as Paget’s 
disease, fibrous dysplasia and malignancy (6). These tumors are distinctly difficult to manage 
due to the extensive dural component, making complete surgical excision challenging and 
resulting in high recurrence rates. Sphenoid wing meningiomas  may spread secondarily into  
the orbit, superior orbital fissure, cavernous sinus and intracranially (6). 
Studies reporting the natural history of spheno-orbital meningiomas have shown that these 
tumours are generally slow growing with an annual growth rate of 0.3cm3 per year (7). 
The average size of tumors measured on CT scan at presentation has been reported to be 
 
3.4cm (8).  Although tumor growth is unpredictable various factors have been shown 
to be associated with increased growth rates i.e. younger age at presentation and a large 
soft tissue component compared to bony involvement (7). 
 
 
 
Sphenoid wing meningiomas commonly occur between the ages of 36 and 70 years. They occur more 
frequently in females with a female to male ratio   of   2.8:1 (4, 9).  Patients with neurofibromatosis 
type 2 (NF-2) and multiple endocrine neoplasia type 1 (MEN-1) are at a greater risk of developing 
meningiomas (10). Meningiomas occur in NF-2 patients due to a mutation of the tumour suppressor 
gene located on chromosome 22.  They have a 75% lifetime risk of developing meningioma (11). 
Other risk factors for menigioma include exposure to ionizing radiation, hormonal factors, breast 
cancer, increased body mass index (BMI) and head trauma (12-15). 
 
Meningioma tumor growth has been postulated to be influenced by female  sex hormones  (16). 
The higher incidence of meningiomas in females, an increased tumor growth rate during 
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pregnancy and a possible association between breast cancer and meningioma may support 
tumor hormone responsiveness (16). It is well established that most meningiomas express 
progesterone receptors and generally lack estrogen receptors (16). It has been demonstrated 
that the presence of progesterone receptors is a good prognostic tumor indicator and is 
associated with improved progression free survival (16). Meningiomas that show negative 
progesterone expression are more likely to be malignant and have a high mitotic index (16). 
There is no correlation between estrogen receptors and prognostic outcomes (16). 
Interestingly, spheno-orbital meningiomas have been reported to have a greater female 
predominance and recurrence risk compared to meningiomas in other sites (7). The 
identification of progesterone receptor expression in meningioma has led to the use of 
hormonal therapy as part of the medical management. Mifepristone, an anti-progesterone 
agent, has been used in the treatment of meningioma and was found to be of benefit in diffuse 
meningiomatosis (17). However mifepristone has not been shown to reduce tumor size and 
provide symptom relief in patients with meningioma (17). 
 
 
Spheno-orbital meningiomas may be associated with hyperostosis of the sphenoid wing, a 
phenomenon well characterized occurring in 25 to 49% of cases (9, 18). Hyperostosis is 
thought to occur as a result of direct invasion of the tumor into bone via the Haversian canals 
and commonly occurs in the lateral third of the sphenoid; however, the exact cause of 
hyperostosis remains unclear (3, 4, 18). The hyperostotic bone is typically large and out of 
proportion compared to the relatively adjacent small tumor. 
 
 
The presenting symptoms of patients with sphenoid wing meningiomas are largely determined 
by the location of the tumor on the sphenoid wing and tumor spread (2). Bony 
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tumor growth may involve the optic canal, superior orbital fissure, roof of the orbit and anterior 
clinoid process. Lateral third tumors commonly present with proptosis and medially situated 
tumors are more likely to present with visual disturbances due to the close proximity to the 
optic nerve (2). Proptosis is the most common presenting symptom in spheno-orbital 
menigioma ranging from 33-95% of cases and may occur in isolation (7, 19-21). Progressive 
proptosis may result in cosmetic deformity. Even if proptosis is not reported clinically it is 
further detected on CT scan with any average of 5.5mm at presentation (22). Proptosis is likely 
attributed to a number of causes including periorbital tumor invasion, intraorbital tumor spread, 
ophthalmic vein thrombosis and hyperostotic bony change of the sphenoid & orbital bones (7, 
18, 23). Visual loss, occurring in 40-60% of cases, is related to tumor infiltration into the optic 
canal and compression of the optic nerve resulting in a compressive optic neuropathy rather 
than intraorbital tumor spread (23). Patients may also present with diplopia, ptosis and orbital 
pain, all of which may impact quality of life (18). 
 
 
The management of sphenoid wing meningioma includes observation, surgery and radiation 
therapy (10). It has been reported that small incidental tumors that are asymptomatic may be 
observed due to their slow growing benign nature. Saeed et al, reported that 35% of patients 
with spheno-orbital menigioma did not have further deterioration in vision with active 
observation (7). The disadvantages of conservative management are that tumor progression is 
unpredictable and age of presentation (4th decade) allows time for further tumour growth.  Due 
to the advancement in imaging and surgical expertise surgical excision has become the 
mainstay of treatment (10). 
In patients undergoing surgery for sphenoid meningioma the standard of care has been 
complete tumor resection (10). However due to the nature of tumor spread and close 
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proximity to the optic nerve, superior orbital fissure, cavernous sinus and dura, complete 
resection is not always possible and is often associated with significant morbidity (10). 
Champange et al, showed that gross total resection is less likely with large meningiomas of 
more than 6cm and involving major cerebral blood vessels. The study showed that total 
resection via an open approach was only achieved in a minority of cases and was associated 
with a higher recurrence rate (24). Therefore, the paradigm of meningioma surgical resection 
has evolved with time due to the understanding of the biology of the tumor. Although benign, 
they are locally invasive into surrounding bone and dura. Thus, complete surgical resection is 
challenging, associated with an increased risk of post-operative complications, high residual 
tumor and recurrence rates post-surgery (25). Tumors that partly encase or invade multiple 
cerebral vessels are not resectable and have an increased risk of postoperative cerebrovascular 
accident (24). In addition, tumors that invade the superior orbital fissure (SOF) or cavernous 
sinus are treated via subtotal resection due to the high risk of ophthalmalgia (26). Therefore, 
the aim of treatment is to address the symptoms, minimize the risk of morbidity and attain 
acceptable functional and cosmetic outcomes (26). The Simpson grading system is typically 
used as the standard for grading tumor resection (27). This grading system is used to predict 
the recurrence rates as it correlates directly with the extent of the tumor resection (27). Grades 
I to V range from gross total resection (I) to simple decompression (V). The rates of recurrence 
for grades I, II, III, IV are 9%, 16%, 29% and 39% respectively (27). 
 
 
Magnetic resonance imaging is used to assess sphenoid wing meningiomas prior to treatment 
to determine the extent of the tumour and the degree of attachment to surrounding brain 
parenchyma (2). CT scan may be used to assess the degree of hyperostotic bone and aid in 
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pre-operative planning (9). Standard open surgical approaches include variations of the 
frontotemporal (pterional) approach, lateral orbitotomy and open extradural optic nerve 
decompression followed by orbital reconstruction using autologous split calvarial bone grafts, 
titanium mesh or non-metallic orbital prostheses (4, 21). Open craniotomy has been shown  to 
improve proptosis in up to 96% of cases and is dependent on the extent of tumor resection (26). 
Freeman et al showed a reduction in proptosis in 86% of cases (26). Scarone et al, reported an 
initial improvement in proptosis in 90% of cases, however over time there was a worsening of 
proptosis in 50% of cases (22). Shrivastava et al, reported a remarkable reduction in proptosis 
in a large number of patients. Nevertheless visual acuity only improved in 28% of patients and 
remained unchanged in 72% of cases (21). Reports of improvement in vision in the literature 
are varied i.e. from 21–74% improvement. Although there is a lack of objectively reported data 
(26). Postoperative resolution of opthalmoplegia has been reported in 68% of cases in a series 
of 25 patients (21). However open surgical approaches are associated with significant 
morbidity, new onset cranial nerve neuropathy and a recurrence rate of up to 10% (4). Major 
complications reported include CSF leak, epilepsy, trigeminal neuralgia & new onset 
opthalmoplegia (28). 
 
 
Gross total resection may not always be possible due to the intimate anatomical relationship to 
underlying neurovascular structures necessitating subtotal resection (2). It is interesting to note 
that tumor recurrence has been shown to be unlikely in cases where subtotal resection has been 
performed despite the presence of an aggressive histological tumor grade and in the absence of 
additional therapy (2). This has led to the hypothesis that it is possible that tumor remnants 
may remain dormant and cease to grow. Nonetheless, further research is necessary to determine 
the key factors and molecular mechanisms involved in the process (2). It has 
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been demonstrated that adequate control, defined as an 80% control rate over a period of 8 
years post-operatively, can be achieved of residual tumor using adjuvant radiotherapy or 
radiosurgery, supporting the efficacy of a more conservative subtotal resection (2). Adjuvant 
radiotherapy for the treatment of menigioma has shown to reduce disease progression. 
Radiation therapy has been used to treat residual menigioma post subtotal resection where vital 
neurovascular structures are intimately involved. There is currently no consensus on the timing 
of adjuvant radiotherapy (26, 29). Some authors advocate immediate post-operative radiation 
therapy and have shown to improve progression free survival compared to patients who did not 
receive post-operative radiotherapy (29). Others promote a conservative approach and 
commence radiation when recurrence is evident (26). 
 
 
In 2010 Moe et al, popularized the use of transorbital neuroendoscopic surgery (TONES). This 
approach allows for multiportal endoscopic access around the eye to access skull base 
pathology i.e. lateral based tumours, repair of CSF leak and optic nerve decompression (30). 
Using this approach, a novel minimally invasive endoscopic surgical approach for sphenoid 
wing meningiomas has recently been described and shown to improve visual acuity and reduce 
proptosis (31, 32). Vision improved with a 2.7 line increase on Snellen chart and proptosis was 
reduced on average by 3.5mm at 6 weeks postoperatively (32). The above procedure addresses 
the most common symptoms namely, proptosis, visual loss and pain. Proptosis is addressed by 
using an extended superior eyelid approach to access the lateral tumor component and to 
remove hyperostotic bone. Furthermore, stabilization of vision is achieved by early 
decompression of the optic canal via a medial optic canal decompression. The surgery involves 
a combined method utilizing both an endo-orbital as well as an endonasal transsphenoidal 
approach (31, 32). Recently Dallan et al, reported the safety and 
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feasibility of using an endoscopic transorbital approach for the treatment of spheno-orbital 
menigioma (25). 
 
 
Although transorbital endoscopic resection of sphenoid wing menigioma have shown 
promising results to improve vision and reduce proptosis, there is a lack of published data on 
the long-term outcomes. Therefore, the aim of this study was to retrospectively determine the 
long-term outcomes of vision and proptosis at one year, using an endoscopic transorbital 
approach in patients routinely undergoing subtotal endoscopic resection of sphenoid wing 
menigioma and to describe the surgical approach. 
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Abstract 
 
 
 
Sphenoid wing meningiomas are benign tumors that result in proptosis, visual impairment and 
pain. Traditional open surgical approaches are associated with significant morbidity. 
Transorbital endoscopic surgery has been developed as a minimally invasive approach to gain 
access to these tumors and address the main presenting symptoms. The aim of the study was 
to assess long term vision and proptosis outcomes in patients undergoing a transorbital 
endoscopic resection of sphenoid wing meningioma using a combined endonasal, 
precaruncular and extended superior eyelid approach and to describe the surgical approach. 
 
 
Materials & Methods
 A retrospective chart review was conducted in 21 patients with lateral sphenoid wing 
meningioma at Groote Schuur Hospital & Cape Town Mediclinic from 2015–2019. All patients 
had undergone a transorbital endoscopic subtotal resection (Simpson grade II – IV) by the same 
surgical team. Vision was assessed using a Snellen chart and proptosis measured in mm using 
a Hertel exophthalmometer by an ophthalmologist. Measurements were taken at 6 weeks, 6 
months and at 1 year postoperatively and compared to pre-operative values. Patients were 
categorized according to the WHO classification of vision into group A (blind), group B (low 
vision) & group C (normal vision) according to their pre-operative visual acuity. Non-
parametric statistical tests employing the Wilcoxon Signed-Ranks Test were used for analysis. 
Statistical significance was determined by a confidence interval of 0.95, p = < 
0.05 for both visual acuity (converted to LogMar) and proptosis in mm. 
 
 
 
Results 
 
A total of 21 patient charts were reviewed. The mean age of presentation was 48.8 years (range 
34-79 years), and the majority of patients were female (20/21 = 95%). The most common 
presenting complaints were loss of vision (100%), proptosis (95%) and headache (76%). Pre-
operative visual results were as follows: 10 (48%) in group A (blind), 4 (19%) in group B (low 
vision) and 7 (33%) in group C (normal vision). In group A, 6 (60%) remained unchanged, 2 
(20%) deteriorated & 1 (10%) improved. In group B, 3 (75%) improved, and 1 
(25%) remained stable. In group C, 5 (71%) improved and 2 (29%) remained stable.   
Vision in groups B & C showed no deterioration. Patients in group A showed no benefit 
from optic nerve decompression. Vision in groups B & C showed a statistically significant 
improvement at 6 weeks [95% CI] (p = 0.021). This trend extended to long term follow    
up at 6 months [95% CI] (p= 0.021) and 1 year [95% CI] (p = 0.0054) postoperatively. 
Proptosis initially 16 
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decreased, proving statistical significance at 6 weeks [95% CI] (p = 0.0054) postoperatively. 
The decrease at 6 months (p = 0.08) was not statistically significant and trended towards an 
increase in proptosis by 1 year (p = 0.78) postoperatively. The mean hospital stay was 2.7 days 
(range 2 – 4 days). The majority of tumors were histologically classified as WHO grade I. 
 
 
Conclusion 
 
Endoscopic medial optic canal decompression prior to transorbital multiportal surgery for 
sphenoid wing meningioma stabilizes or improves visual acuity for at least 1 year. Lateral 
orbitotomy via a superior eyelid approach and subtotal tumor resection initially decreases 
proptosis, but in the long term, returns to its preoperative state by 1 year if the main tumor 
component is not addressed. The earlier that medial optic nerve decompression is performed 
and the better the preoperative visual acuity, the greater the likelihood of favorable long-term 
visual outcomes. 
 Keywords: transorbital; spheno-orbital; menigioma 
 
 
 
Introduction 
 
 
 
Sphenoid wing meningioma’s are the most common tumor of the sphenoid wing. They account 
for 13-19% of all primary intracranial neoplasms (2, 4). Cushing and Eisenhardt were the first 
to describe the growth patterns of sphenoid wing menigioma and differentiated between the 
more common globoid and the rarer en plaque entities. En plaque tumors make up 2 -9% of all 
sphenoid wing meningiomas. They are also known as ‘hyperostosing’ or spheno-orbital 
menigioma and are characterized by a thin dural tumor component, which is 
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typically disproportionate to a significant bony hyperostosis of the lateral sphenoid wing (2, 6, 
33). Although the exact nature of hyperostosis is unknown, it should be regarded as direct 
tumor invasion, which is evident by the presence of tumor cells within bony specimens (3, 4, 
6). The tumor typically invades optic canal, orbit, SOF, cavernous sinus and intracranially  (3). 
The location of the tumour and its spread determine the clinical presentation. The most 
common presenting symptom is proptosis, which is present in >90% of cases and may cause 
significant cosmetic deformity. Progressive proptosis is most likely due to the lateral 
hyperostosis of the sphenoid and orbital bone and invasion of the orbit and periorbita. Visual 
loss is the second most common presenting symptom resulting from a compressive optic 
neuropathy. Other symptoms include facial pain, headache, diplopia & ptosis, all of which 
negatively impact on quality of life (7, 21). 
Traditional open surgical approaches include frontotemporal (pterional) approach, lateral 
orbitotomy and extradural optic nerve decompression (4, 21). Despite advancements in open 
microsurgical techniques spheno-orbital meningiomas remain challenging to treat and are 
associated with significant morbidity and high recurrence rates. Complete surgical clearance is 
often not possible once tumor invades the SOF and cavernous sinus. Residual or recurrent 
tumor may be treated with adjuvant radiotherapy, although there is no current consensus on the 
timing of radiation (26, 34, 35). 
Recently a novel minimally invasive endoscopic transorbital approaches have been described 
by the current surgical team to treat sphenoid wing menigioma. The endoscopic transorbital & 
combined endo-nasal approach aims to address the main symptoms of proptosis and visual 
loss. A medial optic nerve decompression is performed to relive compressive optic neuropathy. 
The lateral tumour is removed by an extended superior eyelid approach which allows access 
to the orbital and intracranial tumor (31, 32) . The aim of the study was to 
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retrospectively determine the long-term outcomes of vision and proptosis in patients routinely 
undergoing an endoscopic transorbital resection of sphenoid wing menigioma and to provide a 
detailed description of the surgical technique used. 
 
 
Rationalization for a multiportal approach to sphenoid wing meningiomas 
 
A major advantage of this approach is the ability to stabilize and improve vision by performing 
a medial optic canal decompression prior to addressing the main intracranial and orbital tumor 
components (3). 
Our hypothesis is that a medial optic nerve canal decompression allows for manipulation of the 
main tumor component during the second stage of the surgery, without the risk of compressive 
damage to the optic nerve, which may occur during traditional approaches and may cause worse 
visual outcomes. Removal of the medial sphenoid sinus tumor component  is also only possible 
using an endonasal or precaruncular approach. The superior eyelid approach gives excellent 
and direct access to the superior and lateral hyperostotic orbital walls and orbit itself - structures 
that are often infiltrated by tumor. Other presenting symptoms such as proptosis and pain can 
therefore be addressed at the same time 
by resecting the orbital component of the tumor and removing the lateral and superior  
walls of the orbit, up to temporalis  muscle  and  anterior and middle fossa dura. The 
corridor thus created provides access to the intracranial component of the tumor. This 
multiportal approach potentially allows for resection of all components of  the  tumor 
during a single surgery with no brain retraction required and minimal collateral tissue 
damage while avoiding the need for reconstruction. 
 
 
Step-wise surgical approach 
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1. Medial optic canal decompression (endonasal or multiportal precaruncular and 
endonasal) 
Medial sphenoid wing meningiomas often involve the sphenoid sinus itself and a uni- or bi- 
nostril approach can be used to resect this component. The binostril approach allows for four- 
handed surgery but requires a posterior septectomy as is typically done for transsphenoidal 
pituitary surgery. Using the precaruncular approach in combination with the above approach 
has some advantages. Firstly, these patients often have proptosis and with removal of the 
posterior lamina papyracea, periorbital fascia can herniate into the ethmoid cavity, obscuring 
good visualization of the optic canal. The precaruncular approach allows for a ribbon (dural) 
retractor to be inserted through this portal to protect the orbit and make visualization of the 
bony canal easier (Figure 1a and 1b). A 2nd advantage is the slight difference in angulation 
obtained, allowing for the endoscope and instruments to be manipulated and to converge at the 
target area. It is convenient to keep the endoscope and orbital retractor within the precaruncular 
portal while powered instruments are used at the target area. 
 
 
2. Resection of superior and lateral hyperostotic orbital wall bone through an extended 
superior eyelid approach 
Sphenoid wing meningiomas often involve the superior and lateral orbital walls and optic 
 
canal, with tumor directly infiltrating bone, causing bony hyperostosis leading to compression 
of the orbital apex and optic canal (Figure 2). The superior portal is accessed through an 
extended superior eyelid approach, using the same crease line as for blepharoplasty surgery 
(Figure 3). It is our opinion that it is best to use this incision rather than a retrocanthal or lateral 
canthotomy incision, since sparing of the lateral canthus allows 
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for wider surgical access, quicker healing and less patient discomfort. Crucial steps need to 
be followed to avoid post-operative sequalae such as ptosis and dystopia (36, 37). 
 Use a natural upper eyelid crease line as for blepharoplasty surgery. 
 
 Dissect through skin and orbicularis oculi muscle only and remain just deep to the 
orbicularis muscle until the bony orbital roof is reached. Remain superficial to orbital 
septum and avoid exposing orbital fat. 
 Once deep to the orbicularis oculi muscle, dissection starts at the lateral aspect of the 
incision, going directly onto bone just lateral to the lateral orbital rim (Figure 4). 
 Dissection is initiated at the lateral aspect of the orbit, using scissors to dissect in a 
subperiosteal plane, moving from the lateral orbital rim superiorly, dissecting tissue 
above the superior orbital rim to avoid damage to the levator muscle (Figure 5). This 
technique allows for quick access to the superior orbital rim. The limit of the dissection 
is usually the supra-orbital nerve although this nerve can be mobilized if required. 
 The orbital periosteum is elevated in a lateral-to-medial fashion starting at the lateral 
orbital rim, thereby ‘rolling’ the periosteum over the orbital rim, keeping the 
ligamentous attachments to Whitnall’s tubercle attached to the periosteum. The 
periosteum is resutured at the end of the procedure to prevent dystopia due to lateral 
canthal tendon displacement. 
 Deep within the orbital cavity, periosteum can easily be elevated off the lateral orbital 
wall to firstly identify a recurrent branch of the middle meningeal artery (Figure 6 & 
7). This artery is an important landmark for the SOF. The limit of dissection along the 
lateral wall is the SOF, found 1cm posterior to this artery (Figure 8). It is important not 
to injure the structures entering the SOF and to avoid excessive traction, 
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especially in patients who have no neurological fallout. Excessive tissue retraction 
could cause a superior orbital fissure syndrome. 
 Superiorly, the lacrimal gland is protected by the periorbital fascia that covers it and 
will not be damaged if dissection remains in the subperiosteal plane. Once the gland is 
elevated out of its fossa, this bony area can be drilled away to provide wider access, the 
so called ‘lacrimal keyhole’ area (Figure 9). This is a good space to rest the endoscope 
during surgery. 
 The superior orbital wall can now be resected using a high speed drill - the extent of 
resection depending on bony tumor involvement. The anterior cranial fossa dura is 
exposed from the frontal sinus to the orbital apex if needed. No reconstruction is 
required and any dural pulsations felt should settle within 2 weeks. 
 The inferior limit of dissection is the inferior orbital fissure (IOF). The amount of bone 
requiring resection depends on the extent of the hyperostosis. The area of bone between 
the SOF and the IOF is called the orbital door jamb. It is important to resect all this 
bone until the temporalis muscle is seen anterolaterally, the middle cranial fossa 
posterolaterally and the anterior cranial fossa dura superiorly (Figure 10). The entire 
lateral orbital wall therefore can be resected, leaving 5mm of orbital rim intact laterally 
for cosmetic purposes. 
 
 
 
 
3. Resection of the orbital component through the lateral transorbital portal 
 
It can initially be difficult to differentiate between orbital tumor and orbital fat, muscle and 
fibrotic tissue. It is relatively easy to resect the periorbital fascia up to the SOF but if patients 
have no neurological fallout, it is important to preserve the neurovascular structures to 
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prevent significant complications such as diplopia related to injury to cranial nerves III, IV or 
 
VI. More research is needed with the use of ultrasound and nerve monitoring to assist with 
achieving more complete resection of the orbital component. 
 
 
4. Resection of the intracranial component through the lateral orbital portal 
 
A wide surgical corridor is created once the lateral hyperostotic bone has been drilled away, 
allowing the intracranial component to be resected using either an endoscope or microscope 
(Figure 10). Standard neurosurgical principles apply with regards to the extent of resection, 
preservation of important neurovascular structures and repair of the ensuing cerebrospinal fluid 
(CSF) leak using fat, fascia or synthetic materials. The authors do not use any sealants within 
the orbit. The lateral orbital wall does not require reconstruction as the orbital rim is left intact 
and the aim in most patients is a reduction in proptosis. Access is gained to the anterior and 
lateral aspects of the temporal lobe. 
 
 
Currently there is a lack of published data in the English literature regarding the level of 
reduction in proptosis, visual improvement and gross total resection achieved in patients that 
have undergone the above procedure for sphenoid wing meningiomas (25). 
This study retrospectively determined the extent of reduction in proptosis as well as the 
improvement in visual outcomes in patients routinely undergoing a minimally invasive 
endoscopic transorbital approach for the treatment of sphenoid wing meningiomas. Most of the 
patients underwent initial multiportal surgery in an attempt to salvage vision and reduce 
proptosis while awaiting a craniotomy as definitive surgery for resection of the intracranial 
component. 
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Methods 
 
 
 
Ethics approval was obtained from the Human Ethic Committee, University of Cape Town 
(HREC 345/2017). A retrospective folder review was conducted in 21 patients who had 
undergone transorbital endoscopic resection for sphenoid wing meningioma at Groote Schuur 
Hospital & Cape Town Mediclinic from 2015–2019. All patients were operated on by the same 
multidisciplinary surgical team which included otolaryngology, ophthalmology and 
neurosurgery. All patients had preoperative CT and MRI scans. The procedure included a 
combined endonasal and lateral orbitotomy using a superior eyelid approach. 
 
 
The following data was collected: age, sex, presenting symptoms, comorbidities, history of 
previous radiation or craniotomy. Visual acuity using a Snellen Chart, and proptosis 
measurements using a Hertel exophthalmometer were recorded by ophthalmology and were 
recorded pre-operatively, at 6 weeks, 6 months and 1 year postoperatively. Patients were 
categorized according to WHO classification of vision into “blind”, “low vision” and “normal 
vision”. Tumor specimens were histopathologically analyzed. 
 
 
Statistical Analysis 
 
 
 
Nonparametric test analysis (performed in R) were used. The Wilcoxon Signed-Ranks Test was 
employed to evaluate visual acuity (Snellen fractions converted to logMar values) and 
proptosis in mm. Pre-operative values were compared to values obtained at 6 weeks, 6 months 
and 1 year postoperatively. Patients who were in the blind category preoperatively (group A) 
were excluded from analysis. Only patients who were in the category of low or 
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normal vision (group B & C) were included in the analysis. A p-value of <0.05 was considered 
to be statistically significant. 
 
 
Results 
 
 
 
Patient & Clinical Data 
 
 
 
A total of 21 patients had undergone transorbital endoscopic tumor resection for sphenoid wing 
meningioma. A subtotal resection was performed in all cases (Simpson grade II – IV). The 
mean age at initial presentation was 48.8 years (range 34 – 79 years). Of these 20 (95%) patients 
were female and 1 (5%) was male. Of the 21 patients, 6 (28%) had hypertension, 4 
(19%) had type 2 diabetes mellitus and 3 (14%) had asthma. 
 
 
 
The most common presenting symptom was decreased visual acuity reported by 21 patients 
(100%), followed by proptosis & headache i.e. 20 (95%), 16 (76%) patients respectively (see 
Table 1 for summary of symptoms). The mean duration of symptoms prior to presentation 
was 9 months (range: 3 – 24 months). In 12 (57%) patients, tumors were located on the  
left side and in 9 (43%) patients they occurred on the right. Of the 21-patient cohort, 3 (14%) 
had had a previous craniotomy which included pterional and lateral orbitotomy approaches, 
and 2 (10%) had received previous radiation therapy. All patients had pre- and post-operative 
CT scans. All patients had lateral en plaque sphenoid wing meningiomas, with evidence of 
hyperostosis. CT scan identified 6 (29%) with intracranial extension, 11 (52%) with 
intraorbital extension and 1 (5%) with diffuse meningiomatosis. One resection was 
complicated by superior orbital fissure syndrome postoperatively which resolved 
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spontaneously. This patient had had a previous craniotomy and radiation therapy. There was 
one mortality unrelated to the surgery. There were no other major surgical complications and 
the mean hospital stay was 2.7 days (range 2-4). 
 
 
Visual acuity 
 
 
 
Improvement in visual acuity was defined as vision that remained the same or a single line 
increase on the Snellen chart. The average line improvement of vision was 1.5 at 6 weeks, 
0.8 at 6 months and 1.4 at 1 year postoperatively (Table 2). Patients were placed into categories 
according to the WHO classification for vision, which was determined by their preoperative 
visual acuity (Tables 2 & 3). In Group A (blind), 6 (60%) patients remained unchanged, 1 
(10%) improved and 2 (20%) had further decline in vision by 1 year postoperatively. In Group 
B (low vision), 3 (75%) had improvement in vision and 1 (25%) remained stable. In Group C, 
5 (71%) of patients had improvement in vision and 2 (29%) remained stable. No patients in 
group B & C experienced deterioration in vision. 
 
 
Proptosis 
 
 
 
Twenty (95%) of patients presented with proptosis. The mean proptosis preoperatively was 
23.8mm (range 18-28). The mean proptosis at 6 weeks, 6 months and 1 year were 21.3mm; 
21.1mm and 23.8mm. Even though the average improvement in proptosis was 2.4mm at 6 
weeks, proptosis trended towards preoperative values at 1 year. 
 
 
Statistical analysis 
  
The nonparametric data model shows a statistically significant improvement in visual acuity at 
6 weeks [95% CI] (p = 0.021). This trend extends to long term follow-up at 6 months [95% CI] 
(p= 0.021) and 1 year [95% CI] (p = 0.0054) postoperatively. Proptosis was shown to decrease 
initially proving statistical significance at 6 weeks [95% CI] (p = 0.0054) postoperatively. The 
decrease at 6 months (p = 0.08) was not statistically significant and trended towards an increase 
in proptosis by 1 year (p = 0.78) postoperatively. 
 
 
Histology 
 
 
Nineteen tumors (95%) were WHO grade I 19 and 1 (5%) was WHO grade II. Histological 
examination of hyperostotic bone showed tumor infiltration in 14 (70%) patients. Biopsies of 
periorbita were positive for meningioma in 6 (28%) patients. 
 
 
 
 
 
 
Discussion 
 
 
Sphenoid wing meningiomas are complex and challenging to manage. Traditional open 
 
neurosurgical approaches have aimed for gross total resection and are associated 
 
with significant morbidity. Open surgical approaches result in brain retraction & 
manipulation, which increases the risk of new onset cranial nerve palsy, epilepsy, stroke and 
mortality (6,24). The open approach may inadequately address the primary symptoms of 
proptosis, decreased visual acuity & pain. 
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Thus a move to subtotal tumor resection has evolved due to the benign nature of the 
disease and the risk of damage to underlying vital neurovascular structures (8). 
 
 
The advent of multiportal transorbital pathways introduced by Moe et al, (2010) has 
permitted a minimally invasive approach to resect sphenoid wing meningiomas (30). A 
superior eyelid approach utilizing the lateral corridor to resect the lateral hyperostotic bone 
has been reported (31, 32). 
 
Since the popularization of  transorbital neuroendoscopic surgery (TONES), there has  been  
limited literature comparing open and extended endoscopic or transorbital surgical 
approaches. Bander et al, in 2018 compared endoscopic endonasal & transcranial approaches 
to meningiomas of the tuberculum sella & planum sphenoidale. The study demonstrated that 
endoscopic resection resulted in statistically significant improvement or stabilization of 
vision compared to open craniotomy.  In addition, there was less brain trauma and seizures 
with the endoscopic approach (42). Park et al, 2020 retrospectively compared an endoscopic 
transorbital approach and an open mini-pterional approach for sphenoid wing meningioma. 
A total of 24 patients were reviewed, 11 patients had undergone tumor resection via an 
endoscopic approach and 13 via open approach. Results showed that there was no difference 
in post-operative morbidity. However, the endoscopic transorbital approach showed 
significantly reduced intraoperative blood loss, reduced surgical time & shorter 
hospitalization. There was no difference in tumor regrowth or recurrence rate between the 
two approaches. It was concluded the endoscopic approach provided certain advantages over 
the open approach i.e. allowing for bony decompression, early tumor devascularization and 
direct tumor access without the need for brain retraction (43).  Limitations of this study 
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included the lack of comment on  outcomes with regards to visual acuity, proptosis, pain and 
cranial nerve fallout.  
Despite the advantages of the endoscopic approach, there remains a role for open craniotomy, 
combined or staged procedures. Open craniotomy may be considered in patients with SWM 
with a large intracranial tumor component and patients with complete encasement of vital 
neurovascular structures. Park et al, 2020 proposed the following indications for an 
endoscopic transorbital approach for SWM i.e. tumor of any size, hyperostosis, orbital tumor 
invasion, incomplete encasement of cranial nerve & vital vasculature and patients with 
aesthetic & functional concerns (43). As neurosurgeons become more experienced
 with the TONES approach, indications will expand & limitations will be defined.   
 
 
In the patients in this study, the goal of surgery was to address the presenting symptoms 
namely loss of vison and proptosis, while they were awaiting definitive neurosurgical 
management. In all cases a subtotal resection was performed (Simpson grade II – IV). 
Complete microscopic surgical clearance was not possible due to extensive dural 
involvement, and in most cases the dura was cauterized with bipolar. 
 
 
It is well documented that meningiomas occur more commonly in females compared to 
males. In our study 95% of patients were female between the ages of 34 and 79 years. This 
correlates with other studies showing a similar demographic and reports that >90% of  
patients with sphenoorbital menigioma are female (4, 9, 10). 
 
 
In the current study the most common presenting symptom was decline in vision (100%) 
followed by proptosis (95%). This differs from other studies that report a higher percentage 
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of proptosis as the most common symptom, and visual impairment ranging between 40 – 
60% in lateral sphenoid wing tumors (7, 18, 23). Dallan et al reported proptosis to be the 
most common presenting symptom (100% of their cases) while 42.8% presented with   
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visual impairment (25). Our findings could be explained by the delayed presentation in South 
Africa, extended duration of symptoms, extensive disease and large number (52%) of  patients 
with intraorbital tumor extension. 
 
 
There was a statically significant improvement in visual acuity in groups B and C at all 
postoperative time intervals i.e. 6 weeks, 6 months and 1 year [95% CI] (p = 0.0054). If 
patients were category A or blind preoperatively, it was less likely that their vision would 
improve and their long-term outcomes were poor. Two category A patients had further 
deterioration in vision; 1 had diffuse meningiomatosis and the other WHO type II 
meningioma, which are both aggressive forms of the disease. It is possible that subsequent 
tumor growth had occurred post-resection which resulted in further decline in vision. In 
addition, patients in this group were older, had a longer duration of symptoms and evidence 
of optic nerve atrophy compared to groups B and C. One patient had improved vision 
postoperatively despite presenting with blindness. This patient was young (36 years), had a 
short duration of symptoms (3 months) and had no evidence of optic atrophy. These factors 
may have played a role in the ability of the optic nerve to recover from a compressive optic 
neuropathy following decompression. 
 
 
In addition, it was noted in our study population that the poorer the preoperative vision the less 
likely vision would improve in the long term (Group A). The trend showed that the better the 
preoperative vision the more favorable the long-term vision outcomes, with most patients 
showing an improvement in visual acuity in group C. Additionally some patients showed a 
further improvement in vision between 6 weeks and 1 year, which would suggest a long-term 
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recovery in optic nerve function. Vision was also shown to stabilize in groups B and C 
with no further decline at 1 year. These findings were consistent with the literature (38). 
 
 
In a systematic review and meta-analysis of visual outcomes following optic nerve 
decompression for chronic compressive optic neuropathy, it was reported that at least 60% of 
patients will show some improvement in vision. The factors that were statistically significant 
in predicting improvement were clinical factors i.e. absence of optic disc atrophy and small 
tumor size. Positive surgical factors included primary resection, a soft tumor consistency, a 
clear dissection plane, absence of tumor in the cavernous sinus and a complete tumor excision 
(38). Age and gender were not shown to have predictive value in determining visual outcomes. 
The duration of symptoms was shown to play a role in visual outcomes i.e. the longer the 
duration of symptoms the greater the chance of poor postoperative vision. Finally, preoperative 
vision status was noted to be of value to predict outcomes i.e. the worse the preoperative vision, 
the less likely vision will improve postoperatively. However if vision is on the poorer side 
preoperatively there is a small chance it may improve (38). 
 
 
Shrivastava et al reported an improvement in visual acuity in only 28% and vision remained 
unchanged in 72% of cases when employing optic nerve decompression for sphenoid wing 
meningioma using an open surgical approach, (21). On review of the literature there is a wide 
range of improvement in visual outcomes in patients with sphenoid wing meningioma using      
an  open  craniotomy approach i.e. 28 – 70 % (9, 20, 39-41). Mariniello et al reported that 
vision improved in 50% of cases, remained the same in 36% and deteriorated in 14% of cases 
in 36 patients undergoing open optic  nerve  decompression  via  a  supraorbital-  pterional  
approach. Outcomes were thought to be predicted by extent of optic canal invasion, tumor 
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grade and Simpson grade of tumor resection. The intraorbital portion of the tumor is thought 
to be a less significant factor in visual outcomes. They therefore advocated for early optic nerve 
decompression (23). 
 
 
There is less published data on visual outcomes using a transorbital endoscopic approach for 
sphenoid wing meningioma. Our surgical unit previously reported an average line increase of 
2.7 in the Snellen chart and an average reduction in proptosis of 3.5 mm 6 weeks 
postoperatively (32). Almeida et al, reported 2 cases using a endoscopic transorbital technique 
via superior eyelid approach for sphenoid wing meningioma and showed an improvement in 
visual acuity and proptosis at 1 month postoperatively (33). Dallan et al, reported 14 cases of 
sphenoorbital meningioma treated via transorbital endoscopic and superior eyelid approach 
and demonstrated that the approach was feasible and safe. In 3 (21.4%) patients complete tumor 
resection was achieved. The tumor volume removed as measured by CT scan ranged between 
55–100% (25). 
 
 
Proptosis is caused by tumor infiltration of bone resulting in a hyperostotic reaction of the 
sphenoid wing. Hyperostosis displaces the globe from medially and by mass effect may stretch 
the optic nerve and has the potential to compromise vision (32, 39). Our results for proptosis 
were promising in the initial postoperative period with an average reduction of 2 mm which is 
statistically significant [95% CI] (p = 0.0054). However, it was noted that proptosis recurred 
by 1 year. This may be due to a number of factors i.e. subtotal tumor resection, growth of 
residual tumor and intraconal tumor involving the periorbita. Open craniotomy or lateral 
orbitotomy approaches have been shown to reduce proptosis. Scarone et al studied 30 patients 
with sphenoid wing meningiomas who had undergone open craniotomy 
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to remove hyperostotic bone. In their series proptosis improved in the short term (average 1 
year) but in the long term (61 months) up to 50% of patients showed a worsening of proptosis 
despite Simpson grade I and II resections (22). Little has been published on the reduction in 
proptosis using the transorbital approach. Research carried out by our surgical unit 
demonstrated a reduction in proptosis in the early postoperative period of 3.5 mm on average 
(31). 
 
 
Conclusions 
 
 
 
This is the first report of long term outcomes of vision and proptosis using a transorbital 
endoscopic approach for the treatment of lateral sphenoid wing meningioma. Our results show 
that medial optic nerve decompression dramatically improves vision in patients who present 
with low to normal vision with minimal morbidity. This benefit is maintained for at least 1 year 
postoperatively. Patients with evidence of optic nerve atrophy and who are blind preoperatively 
did not benefit from optic nerve decompression. The earlier one performs optic nerve 
decompression the more favorable the long term vision outcomes. Proptosis was shown to 
improve postoperatively but recurred with time, returning to preoperative measurements by 1 
year if a subtotal resection was performed. Of interest, vision remained stable or further 
improved despite an increase in proptosis over time. This supports the indication of optic nerve 
decompression as it buys time while awaiting definitive craniotomy or a more extensive 
resection using the transorbital route. 
 
 
These results are valuable in selecting patients who would benefit from surgery and for 
preoperative counselling. 
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Based on our results we therefore recommend early medial optic nerve decompression to 
preserve or improve vision. It is however clear that these complex tumors require 
multidisciplinary teams for effective management as they may require multimodal treatment 
i.e. medial optic nerve decompression to improve vision, craniotomy to address lateral 
hyperostosis and postoperative radiation for residual disease. 
 
 
Limitations & Future Research 
 
 
 
We acknowledge that the retrospective nature and small sample size are limiting factors. These 
are however rare tumors, and this represents the largest sample of patients reported in the 
English literature. Future research is required to determine the role of progesterone in sphenoid 
wing meningioma. As technology and expertise advance, more likely total resection will 
become possible via a transorbital approach. A prospective trial comparing craniotomy and 
transorbital approach is needed. 
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Tables & Figures 
 
 
 
 
Visual impairment 21 (100%) 
Proptosis 20 (95%) 
Headache 16 (76%) 
Facial Pain 15 (71%) 
Diplopia 3 (14%) 
Ptosis 1 (5%) 
Blocked nose 1 (5%) 
Epiphora 1 (5%) 
Table 1: Presenting symptoms
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Patient VA 
Pre 
op 
VA 
6 
weeks 
post op 
VA 
6 
months 
post op 
VA 
1 
year 
post 
op 
Proptosis 
(mm) 
Pre op 
Proptosis 
(mm) 
6 weeks 
post op 
Proptosis 
(mm) 
6 months 
post op 
Proptosis 
(mm) 
1 year 
post op 
1 NLP NLP NLP NLP 28 28 26 28 
2 CF 6/36 NLP NLP 22 19 19 26 
3 HM 6/9 HM NLP 24 22 22 24 
4 6/6 6/5 6/5 6/5 24 22 23 24 
5 NLP NLP NLP NLP 25 21 21 27 
6 CF 6/12 6/12 6/12 23 21 21 21 
7 6/12 6/9 6/9 6/6 24 23 20 20 
8 6/18 6/18 6/18 6/18 18 18 18 18 
9 NLP NLP NLP D 24 21 21 D 
10 6/12 6/12 6/12 6/12 23 20 21 23 
11 6/12 6/9 6/9 6/6 22 19 18 22 
12 NLP NLP NLP NLP 29 27 18 29 
13 6/12 6/9 6/9 6/9 24 22 22 23 
14 6/18 6/18 6/18 6/5 21 20 20 25 
15 6/36 6/24 6/18 6/18 22 20 19 20 
16 NLP NLP NLP NLP 28 26 26 28 
17 HM HM HM HM 24 20 19 22 
18 6/9 6/6 6/6 6/6 22 19 20 22 
19 CF CF CF CF 25 21 21 23 
20 6/60 6/24 6/24 6/24 28 22 23 28 
21 6/12 6/12 6/12 6/12 21 18 27 22 
NLP (No light perception); HM (Hand movements); CF (counting fingers) 
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Table 2: Visual acuity (VA) fractions according to Snellen Chart pre-operatively, 6 weeks, 6 
 
months and at 1 year postoperatively. Proptosis (mm) measured by Hertel exophthalmometer 
preoperatively, and 6 weeks, 6-8 months and 1 year post-operatively. 
 
 
 
Category VA Pre op Number of Patients 
A 
 
Blind 
NLP/HM/CF 10 
 
(48%) 
Unchanged / 
 
Stabilized 
6 (60%) 
Deteriorated 2 (20%) 
Improved 1 (10%) 
B 
 
Low 
Vision 
6/18 – 6/60 4 
 
(19%) 
Unchanged / 
 
Stabilized 
1 (25%) 
Deteriorated 0 
Improved 3 (75%) 
C 
 
Normal 
vision 
6/6 – 6/12 7 (33%) Unchanged / 
 
Stabilized 
2 (29%) 
Deteriorated 0 
Improved 5 (71%) 
 
 
Table 3: Category of VA preoperatively & number of patients in which vision had either 
 
remained unchanged or stabilized, improved or deteriorated by 1 year postoperatively 
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Figure 1a and 1b: Multiportal surgery (1a) using a precaruncular and unilateral endonasal 
 
approach to decompress the medial optic nerve canal (right eye). Instruments converge on 
the target area (1b) 
 
 
 
 
 
 
 
 
 
Figure 2: Sphenoid wing meningioma with bony hypFeirgousrteos1ias causing compression at the 
 
optic canal and orbital apex 
 
 
 
 
 
 
 
Figure 3: The superior eyelid incision is made as for blepharoplasty surgery using a natural 
 
crease line. The incision can be extended laterally to spare the lateral canthus of the eye 
Figure 1a 
Figure 1b 
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Figure 4: Dissection starts on the lateral orbital  rim to prevent damage to the levator muscle 
 
 
 
 
 
Figure 5: The periosteum is  elevated off the orbital rim from laterally to medially around the 
 
orbital rim and then off the superior orbital rim 
 
 
 
 
 
Figures 6: A recurrent branch of the middle meningeal artery in a cadaveric specimen (left 
 
eye) 
 
 
Figure 7: Recurrent branch of the middle meningeal artery (right eye), 1cm anterior to the 
 
SOF 
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Figure 8: The SOF is 1cm posterior to the recurrent branch of the middle meningeal artery 
 
(left eye in cadaveric specimen) 
 
 
 
 
 
Figure 9: Lacrimal keyhole area is drilled away once the lacrimal gland is dissected out of 
 
it’s fossa 
 
 
 
 
 
 
44  
Figure 10: The lateral orbital corridor: the thick area of bone requiring removal to 
expose the temporalis muscle anterolaterally (arrow), the middle cranial fossa 
posteriolaterally 
(double arrow) and the anterior cranial fossa dura superiorly (Left eye) 
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Author Instructions 
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read the instructions carefully and observe all the directions given. Failure to do so may result 
in unnecessary delays in publishing your article. 
SUBMISSION CHECKLIST 
 
All manuscripts must be submitted at the following link: 
 
 ☐ AUTHOR INFORMATION 
 
- All authors: full name, degrees, department, affiliation, e-mail address - 
Corresponding author: mailing address, telephone number 
 ☐ MANUSCRIPT FILE 
 
- Must be digital - hard copy submissions are not accepted 
 
 ☐ ABSTRACT AND KEYWORDS 
 
- See the section Article Types for word limits 
 
 ☐ REFERENCES 
 
- Cited sequentially in AMA style 
 
 ☐ FIGURES AND TABLES 
 
- Cited sequentially and included in the main document 
 
 ☐ ART FILES 
 
- Must be saved separately from the main document 
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 ☐ PERMISSIONS 
 
- Required if you plan to reproduce content from a published source or include a 
photograph of a patient 
- Patient permission forms available at www.thieme.com/journal-authors 
 
MANUSCRIPT FORMAT 
 
General Guidelines 
 
 · You must submit a digital copy of your manuscript. Hard copy submissions are not 
accepted. 
 · Keep the format of your manuscript simple and clear. We will set your 
manuscript according to our 
style—do not try to “design” the document. 
 
 · The manuscript, including the title page, abstract and keywords, text, references, 
figure captions, and 
tables should be typewritten, double-spaced in 12-point font with 1-inch margins all 
around and saved 
as one file. 
 
 · Each figure should be saved as its own separate file. Do not embed figures within 
the manuscript file. 
This requires special handling by Thieme’s Production Department. 
 
 · Keep abbreviations to a minimum and be sure to explain all of them the first time 
they are used in the 
text. 
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 · The manuscripts should be written in American English. 
 
 · The authors should use Système International (SI) measurements. For clarity, 
nonmetric equivalents 
may be included in parentheses following the SI measurements. 
 
 · Use generic names for drugs. You may cite proprietary names in parentheses along 
with the name and 
location of the manufacturer. 
 
 · Credit suppliers and manufacturers of equipment, drugs, and other brand-name 
material mentioned in 
the manuscript within parentheses, giving the company name and primary location. 
 
 
 
Title Page 
 
 · This journal adheres to a single-blinded peer-review policy. The title page should be 
included in the main document. 
 · The title page should list the article title and the corresponding author’s full name, 
degree, title, department, affiliation, mailing address, e-mail address, and telephone 
and fax numbers. It should also list the full name, degree, title, department, and 
affiliation of every co-author. 
Abstract and Keywords 
 
See the section Article Types for word limits. 
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The abstract should briefly outline the content of the article and any conclusions it 
may reach. It should contain the following elements: Objectives, Design, Setting, 
Participants, Main Outcome Measures, Results, Conclusions. 
The keywords should be words a reader would be likely to use in searching for the 
content of the article. 
Main Document 
 
 · Please clearly distinguish the hierarchy of headings within the manuscript by using 
capital letters, underline, italic, and bold styles as necessary. 
 · As needed, use italic, superscripts, subscripts, and boldface, but otherwise do not use 
multiple fonts and font sizes. 
 · Do not insert page or section breaks except where noted in the Author Instructions. 
 
 · Use hard returns (the Enter key) only at the end of a paragraph, not at the end of a 
line. Allow lines of 
text to break automatically in your word-processing software. Do not justify your text. 
 
 · Use only one space, not two, after periods. 
 
 · Create tables using the Table function in Microsoft Word. 
 
Thieme Editing Services 
 
Thieme offers a language editing service for manuscripts, abstracts and theses in 
partnership with Enago, a world-leading provider of author services to researchers 
around the world. Authors can choose from a range of editing services and get their 
manuscripts edited by Enago’s professional medical editors. Authors that wish to use 
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this service will receive a 20% discount on all editing services. To find out more 
information or get a quote, please visit https://www.enago.com/thieme 
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Figure Captions 
 
 · Figures include photographs or radiographs, drawings, graphs, bar charts, flow 
charts, and pathways, but NOT lists or tables. 
 · Figures must be cited sequentially in the text. Number all figures (and corresponding 
figure captions) sequentially in the order they are cited in the text. 
 · Figure captions should be written after the reference list. Insert a page break between 
the end of references and the start of figure captions. 
 · Figure captions should include a description of the figure and/or each lettered part 
(A, B, etc.) and of any portions of the figure highlighted by arrows, arrowheads, 
asterisks, etc. 
 · For a figure borrowed or adapted from another publication (used with permission), 
add a credit line in parentheses at the end of each figure legend. This credit line 
should be a complete bibliographic listing of the source publication (as a reference), 
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or other credit line as supplied by the copyright holder. For example (Reprinted with 
permission from Calfee DR, Wispelwey B. Brain abscess. Semin Neurol 
2000;20:357.) 
Tables 
 
 · Data given in tables should be commented on but not repeated in the text. Be sure 
that lists or columns of related data are composed in a word-processing program like 
the rest of the text. 
 · Do not intersperse tables in the text. Tables should appear after the figure captions. 
 
Insert a page break between the end of the figure captions and the start of the tables. 
 
 · Tables must be double-spaced and numbered in the same sequence they are cited in 
the text. A short descriptive title should be provided for each table. 
 · If a table contains artwork, supply the artwork separately as a digital file. 
 
 · For tables borrowed or adapted from another publication (used with permission), add 
a credit line as the 
first footnote beneath each table. This credit line should be a complete bibliographical 
listing of the source publication (as a reference), or other credit line as supplied by the 
copyright holder. For example, “Reprinted with permission from Calfee DR, 
Wispelwey B. Brain abscess. Semin Neurol 2000;20:357.” (“Data from . . .” or 
“Adapted from . . .” may also be used, as appropriate.) 
 · Other footnotes for tables should be indicated in the table using superscript letters in 
alphabetical order. 
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 · Any abbreviations used in the table should be explained at the end of the table in a 
footnote. 
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DIGITAL ARTWORK PREPARATION 
 
General Guidelines 
 
 · t is best to use Adobe Photoshop to create and save images, and Adobe Illustrator for 
line art and labels. 
 · Do not submit art created in Microsoft Excel, Word, or PowerPoint. These files 
cannot be used by the 
typesetter. 
 
 · Save each figure in a separate file. 
 
 · Do not compress files. 
 
 · All black-and-white and color artwork should be at a resolution of 300 dpi (dots per 
inch) in TIFF format. 
Line art should be 1,200 dpi in EPS or TIFF format. Contact the Production Editor at 
Thieme if you are unsure 
of the final size. 
 
 · It is preferable for figures to be cropped to their final size (approximately 31⁄2 inches 
for a single column and 
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up to 7 inches for a double column), or larger, and in the correct orientation. If art is 
submitted smaller and then has to be enlarged, its resolution (dpi) and clarity will 
decrease. 
Note: Lower resolutions (less than 300 dpi) and JPEG format (.jpg extension) for 
grayscale and color artwork are strongly discouraged due to the poor quality they 
yield in printing, which requires 300 dpi resolution for sharp, clear, detailed images. 
JPEG format, by definition, is a lower resolution (compressed) format designed for 
quick upload on computer screens. 
Black-and-White Art 
 
 · Black-and-white artwork can be halftone (or grayscale) photographs, radiographs, 
drawings, line art, graphs, and flowcharts. Thieme will only accept digital artwork. 
 · If possible, do not send color art for conversion to black-and-white. Do the 
conversion yourself so that you can check the results and confirm in advance that no 
critical details are lost or obscured by the change to black-and-white. 
 · For best results, line art should be black on a white background. Lines and type 
should be clean and evenly dark. Avoid screens or cross-hatching, as they can darken 
or be uneven in printing and lead to unacceptable printing quality. 
Color Art 
 
 · Color illustrations are expensive to produce and usually cannot be accepted unless 
the author is willing to cover the additional production costs incurred. Please check 
with the Editor in Chief or Thieme for details. We will convert color illustrations to 
black-and-white unless we receive a letter from the author assuming responsibility for 
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the cost of printing color. Upon request, we will provide you with a cost estimate for 
the color printing. 
 · All color artwork should be saved in CMYK, not RGB. 
 
Art Labels 
 
 · Arrows, asterisks, and arrowheads (or other markers) should be white in dark or 
black areas and black in light or white areas, and large in size. If not, these 
highlighting marks may become difficult to see when figures are reduced in size 
during the typesetting process. 
 · Use 1-point (or thicker) rules and leader lines. 
 
 · Capitalize the first word of each label and all proper nouns. Consider using 
all capitals if you need a higher 
level of labels. 
 
 · Where there are alternate terms or spellings for a named structure, use the most 
common one and make 
sure it is consistent with what is used in the text. 
 
 · Avoid using multiple fonts and font sizes for the labels; use only one or two sizes of 
a serif font. 
 
 
As the author, it is your responsibility to obtain all permissions, pay any permission fees, 
furnish copies of permissions to Thieme with your manuscript, and include a credit line at the 
end of the figure caption, beneath the table, or in a text footnote. 
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reproduce all or part of any publication. The reproduction of articles or illustrations without 
prior consent from the publisher is prohibited. 
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institutional review board (IRB) or ethics committee is required, as well as any necessary 
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photograph will be used. If you do not supply this, the identity of the patient must be 
obscured before the image is published; this could interfere with the instructive value of the 
photograph. Patient permission forms are available at www.thieme.com/journal-authors 
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